The Viloxazine Paradox: A Noradrenergic Agent's Journey From Antidepressant Obscurity to ADHD Precision Therapy.

CNS Neurosci Ther · 2026 · PMC13056690 · PMID 41947282

Europe PMC DOI

hedged sentence

0.0710

closest p · 1.4× alpha

0.0710

boldest claim

The sentences

did not reach statistical significancep = 0.071so close (0.05 < p ≤ 0.1)

At study end, the 400 mg group showed a significantly greater mean reduction in ADHD‐RS‐5 total score (−18.3) than placebo (−13.2; p = 0.008) [ 10 ]; the 600 mg group improved (−16.7) but did not reach statistical significance ( p = 0.071) [ 10 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.